BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 24876129)

  • 1. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation.
    Narasimha AM; Kaulich M; Shapiro GS; Choi YJ; Sicinski P; Dowdy SF
    Elife; 2014 Jun; 3():. PubMed ID: 24876129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition.
    Kaulich M; Link VM; Lapek JD; Lee YJ; Glass CK; Gonzalez DJ; Dowdy SF
    Sci Rep; 2021 Jul; 11(1):14736. PubMed ID: 34282211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression.
    Keenan SM; Lents NH; Baldassare JJ
    J Biol Chem; 2004 Feb; 279(7):5387-96. PubMed ID: 14645251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.
    Ezhevsky SA; Nagahara H; Vocero-Akbani AM; Gius DR; Wei MC; Dowdy SF
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10699-704. PubMed ID: 9380698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.
    Clark W; Black EJ; MacLaren A; Kruse U; LaThangue N; Vogt PK; Gillespie DA
    Mol Cell Biol; 2000 Apr; 20(7):2529-42. PubMed ID: 10713176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
    Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
    Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation.
    Leng X; Connell-Crowley L; Goodrich D; Harper JW
    Curr Biol; 1997 Sep; 7(9):709-12. PubMed ID: 9285720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
    Elangovan S; Hsieh TC; Wu JM
    Anticancer Res; 2008; 28(5A):2641-7. PubMed ID: 19035289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy.
    Féliers D; Frank MA; Riley DJ
    Diabetes; 2002 Nov; 51(11):3290-9. PubMed ID: 12401721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase.
    Meng F; Qian J; Yue H; Li X; Xue K
    Cell Cycle; 2016 Jul; 15(13):1724-32. PubMed ID: 27163259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.
    Pan W; Cox S; Hoess RH; Grafström RH
    Cancer Res; 2001 Apr; 61(7):2885-91. PubMed ID: 11306463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
    Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts.
    Gaben AM; Saucier C; Bedin M; Barbu V; Mester J
    Int J Cancer; 2004 Jan; 108(2):200-6. PubMed ID: 14639603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2.
    Lan Z; Sever-Chroneos Z; Strobeck MW; Park CH; Baskaran R; Edelmann W; Leone G; Knudsen ES
    J Biol Chem; 2002 Mar; 277(10):8372-81. PubMed ID: 11726663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication licensing promotes cyclin D1 expression and G1 progression in untransformed human cells.
    Liu P; Slater DM; Lenburg M; Nevis K; Cook JG; Vaziri C
    Cell Cycle; 2009 Jan; 8(1):125-36. PubMed ID: 19106611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor-induced rapid retinoblastoma phosphorylation at Ser780 and Ser795 is mediated by ERK1/2 in small intestine epithelial cells.
    Guo J; Sheng G; Warner BW
    J Biol Chem; 2005 Oct; 280(43):35992-8. PubMed ID: 16126730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
    Fribourg AF; Knudsen KE; Strobeck MW; Lindhorst CM; Knudsen ES
    Cell Growth Differ; 2000 Jul; 11(7):361-72. PubMed ID: 10939590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention.
    Tyagi A; Agarwal C; Agarwal R
    Mol Cancer Ther; 2002 May; 1(7):525-32. PubMed ID: 12479270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression.
    Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW
    Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
    Lin Z; Zhang X; Zhao F; Ru S
    Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.